CME Article: Hydroxyurea for Sickle Cell Disease: Now Is the Time!

Authors: John J. Strouse, MD, PhD


How Many People with Sickle Cell Disease Are Receiving Hydroxyurea? Hydroxyurea is used widely in the United States and Europe as a treatment for sickle cell disease (SCD). Hydroxyurea was approved by in the United States Food and Drug Administration for the treatment of adults with severe sickle cell anemia in 1998 and by the European Medicines Agency for the treatment adults in 2003 and children two years or older in 2007.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Le PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015;62:1956-1961.
2. Nottage KA, Hankins JS, Smeltzer M, et al. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PLoS One 2013;8:e72077.
3. Lanzkron S, Haywood C Jr Fagan PJ, et al. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved 2010;21:277-286.
4. Ritho J, Liu H, Hartzema AG, et al. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Am J Hematol 2011;86:888-890.
5. Tripathi A, Jerrell JM, Stallworth JR. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Pediatr Blood Cancer 2011;56:90-94.
6. Creary SE, Chisolm DJ, Koch TL, et al. Hydroxyurea use in children with sickle cell disease: do severely affected patients use it and does it impact hospitalization outcomes? Pediatr Blood Cancer 2016;63:844-847.
7. Shafer FE, Lorey F, Cunningham GC, et al. Newborn screening for sickle cell disease: 4 years of experience from California' newborn screening program. J Pediatr Hematol Oncol 1996;18:36-41.
8. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
9. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-1672.
10. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
11. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-2363.
12. Lebensburger JD, Patel RJ, Palabindela P, et al. Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia. J Blood Med 2015;6:285-290.
13. Luchtman-Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol 2016;91:238-242.
14. Lanzkron S, Strouse JJ, Wilson R, et al. An evidence-based review for the NIH Consensus Development Conference on Hydroxyurea for the Treatment of Adults with Sickle Cell Disease. Ann Intern Med 2008:0000605-200806170-200800221.
15. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008;122:1332-1342.
16. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001;139:785-789.
17. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014;371:699-710.
18. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285-4291.
19. Lanzkron S, Haywood C Jr Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc 2008;100:968-973.
20. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol 2010;85:611-613.
21. US Department of Health and Human Services. Evidence-based management of sickle cell disease: expert panel report, 2014. Accessed June 27, 2016.
22. Creary SE, Strouse JJ. Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease: A Pocket Guide for the Clinician. Washington, DC: American Society of Hematology, 2014.
23. American Society of Hematology. Accessed June 27, 2016.
24. National Institute for Children' Health Quality. Hydroxyurea: the best hope for sickle cell anemia patients. Published January 6, 2015. Accessed July 7, 2016.
25. Children’ Medical Center. Sickle cell patients and hydroxyurea treatment. Published June 10, 2014. Accessed July 7, 2016.